Cargando…
Ajulemic acid: potential treatment for chronic inflammation
Ajulemic acid (AJA, CT‐3, IP‐751, JBT‐101, anabasum) is a first‐in‐class, synthetic, orally active, cannabinoid‐derived drug that preferentially binds to the CB2 receptor and is nonpsychoactive. In preclinical studies, and in Phase 1 and 2 clinical trials, AJA showed a favorable safety, tolerability...
Autor principal: | Burstein, Sumner H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891661/ https://www.ncbi.nlm.nih.gov/pubmed/29638269 http://dx.doi.org/10.1002/prp2.394 |
Ejemplares similares
-
In vitro metabolism and metabolic effects of ajulemic acid, a synthetic cannabinoid agonist
por: Burstein, Sumner H, et al.
Publicado: (2013) -
Ajulemic acid exerts potent anti-fibrotic effect during the fibrogenic phase of bleomycin lung
por: Lucattelli, Monica, et al.
Publicado: (2016) -
The Potential Effects of Probiotics and ω-3 Fatty Acids on Chronic Low-Grade Inflammation
por: Hutchinson, Ashley N., et al.
Publicado: (2020) -
Dihomo-γ-Linolenic Acid (20:3n-6)—Metabolism, Derivatives, and Potential Significance in Chronic Inflammation
por: Mustonen, Anne-Mari, et al.
Publicado: (2023) -
Interferons and their potential in the treatment of ocular inflammation
por: Mackensen, Friederike, et al.
Publicado: (2009)